

IN THE CLAIMS

Amended claims 1-4, 7, and 9 are shown below. Also attached is a version with markings to show changes made to the claims. Please cancel claim 12 without prejudice or disclaimer.

B1
1. (Twice amended) A composition of (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one comprising (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one in an amount less than 0.5% by weight.

Sub C1
2. (Twice amended) The composition according to claim 1, wherein the amount of (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.25% or less.

3. (Twice amended) The composition according to claim 1, wherein the amount of (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.1% or less.

4. (Twice amended) A process for preparing (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one comprising aging crystals of (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in the presence of water for at least 24 hours.

B2
7. (Twice amended) A pharmaceutical dosage unit comprising a pharmaceutically suitable solid carrier and a composition of (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one comprising (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one in an amount less than 0.5% by weight.

B3
Sub C2
9. (Twice amended) A dosage unit comprising a pharmaceutically suitable solid carrier and (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in an amount of less than 2.50 mg and comprising less than 5% by weight of (7 α , 17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one at a shelf-life of at least 1.5 years.